# US Lower GI Series Market > US Lower GI Series Market Research Report By Application (Gastroenteritis, Colon Polyps, Tumor, Strictures Crohn's Disease, Ulcerative Colitis, others), By Test Types (Double-Contrast, Single-Contrast) and By End Users (Hospitals, Clinics, Laboratories) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.45% - **2024:** $ 382.2 Million - **2025:** $ 399.21 Million - **2035:** $ 616.8 Million - **Key Players:** Bayer AG (DE), Abbott Laboratories (US), Fujifilm Holdings Corporation (JP), Siemens Healthineers (DE), General Electric Company (US), Medtronic plc (IE), Hologic, Inc. (US), Philips Healthcare (NL) **Report ID:** MRFR/Pharma/18427-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-lower-gi-series-market-19974 --- ## Market Summary ## **US Lower GI Series Market Overview** As per MRFR analysis, the US Lower GI Series Market Size was estimated at 52.18 (USD Billion) in 2023. The US Lower GI Series Market Industry is expected to grow from 56.3(USD Billion) in 2024 to 123.57 (USD Billion) by 2035. The US Lower GI Series Market CAGR (growth rate) is expected to be around 7.408% during the forecast period (2025 - 2035). ### **Key US Lower GI Series Market Trends Highlighted** The US Lower GI Series Market is currently witnessing significant trends driven by a growing emphasis on preventive healthcare and early diagnosis of gastrointestinal disorders. Increasing rates of conditions such as colorectal cancer have heightened awareness among both healthcare providers and patients about the importance of diagnostic procedures like lower gastrointestinal series. The US healthcare system continues to push for effective screening programs, particularly for individuals over the age of 50, which is fueling demand for these imaging procedures. Moreover, advancements in imaging technology are enhancing the accuracy and efficiency of lower GI series, making the procedure less invasive and more patient-friendly. The rise of telemedicine has also influenced how patients approach gastrointestinal health, leading to more proactive engagement in health screenings and diagnostic tests. Opportunities exist to expand outreach programs to educate the public about the benefits of early diagnostic procedures, especially in underserved populations, where awareness may be lower. In recent times, there has been a notable trend towards integrated care models that facilitate better communication between specialists and general practitioners. This shift is geared towards improving patient outcomes and ensuring timely referrals for lower GI series when needed. As the healthcare landscape evolves, providers are also exploring partnerships with technology firms to innovate how these procedures are conducted and interpreted, thus enhancing the overall patient experience. The evolving dynamics signify a robust focus on making lower GI series more accessible and effective as part of routine healthcare practices in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Lower GI Series Market Drivers** ### **Increasing Prevalence of Gastrointestinal Disorders** The US [Lower GI Series Market](../../../reports/lower-gi-series-market-771) Industry is experiencing growth due to the rising prevalence of gastrointestinal disorders such as inflammatory bowel disease, colorectal cancer, and irritable bowel syndrome. Recent data from the Centers for Disease Control and Prevention (CDC) indicates that approximately 1.6 million Americans are living with inflammatory bowel disease. This growing patient demographic is driving the demand for diagnostic imaging procedures, including Lower GI Series, as healthcare providers seek accurate methods for diagnosis. Furthermore, organizations such as the American Cancer Society advocate for early screening and detection of colorectal cancer, leading to increased utilization of Lower GI Series. Given that colorectal cancer is the second leading cause of cancer-related deaths in the United States for both men and women, the importance of these diagnostic tools cannot be understated. This trend is projected to continue over the coming years, contributing significantly to the US Lower GI Series Market growth. ### **Technological Advancements in Imaging Techniques** Innovations in imaging technology are a key driver for the US Lower GI Series Market Industry. Advanced imaging technologies such as high-resolution fluoroscopy and digital radiography are being adopted to enhance the accuracy and efficiency of Lower GI Series. These advancements help minimize patient exposure to radiation and improve image quality, thus supporting better diagnostic outcomes. Established organizations like the Radiological Society of North America (RSNA) promote these innovative technologies through educational seminars and training programs, further amplifying their adoption in clinical practice. The continual emergence of new technologies facilitates a transition towards more precise and timely diagnoses, which is expected to significantly boost market growth. ### **Increased Funding for Healthcare Infrastructure** Government initiatives to enhance healthcare infrastructure, particularly in radiology departments, are also fostering growth in the US Lower GI Series Market Industry. The Health Resources and Services Administration (HRSA) has been increasing funding for healthcare facilities, enabling hospitals and clinics to upgrade their imaging equipment and expand their diagnostics services. This investment in healthcare infrastructure allows for more widespread availability and use of Lower GI Series procedures, as patients are experiencing shorter wait times for crucial diagnostic tests. With a stronger focus on preventive healthcare and early detection of diseases, the role of Lower GI Series in the diagnostic landscape is set to expand in the coming years. ## **US Lower GI Series Market Segment Insights** ### **Lower GI Series Market Application Insights** The US Lower GI Series Market, particularly focusing on the Application segment, showcases significant growth due to the rising prevalence of various gastrointestinal disorders. This segment encompasses various conditions, including Gastroenteritis, Colon Polyps, Tumor, Strictures, Crohn's Disease, Ulcerative Colitis, and others. Gastroenteritis, often caused by infections, remains a major concern, contributing to the need for effective diagnostics through lower gastrointestinal imaging, thus driving market demand. Colon Polyps are important due to their association with colorectal cancer; early detection is crucial, leading to increased utilization of lower GI series for preventive screenings. Tumors, whether benign or malignant, require precise imaging techniques for evaluation and treatment planning, thereby emphasizing the importance of this application in oncological settings. Strictures present unique challenges as they may indicate underlying diseases; diagnostic imaging plays a vital role in assessing the severity and appropriate management. Meanwhile, Crohn's Disease and Ulcerative Colitis, which are part of inflammatory bowel diseases, are prevalent in the US population, further propelling market growth as healthcare providers seek advanced imaging solutions for optimal patient care. The US healthcare system’s emphasis on early detection and management of these conditions continues to enhance the significance of the Lower GI Series Market. Overall, with a wide array of applications targeting specific gastrointestinal disorders, this segment reflects a crucial part of diagnostic strategies that are increasingly being adopted across various healthcare settings in the US. The ongoing advancements in imaging technology and the growing awareness among patients regarding gastrointestinal health are expected to further stimulate the Application segment's growth in this dynamic market. Additionally, trends such as increasing healthcare expenditure and a shift towards outpatient diagnostic procedures align with the rising demand for lower GI series, fostering further innovation and investment within this space. The comprehensive nature of the Application segment encapsulates both diagnostic and preventive aspects, thus making it a pivotal focus for market stakeholders looking to harness opportunities in the US Lower GI Series Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Lower GI Series Market Test Types Insights** The US Lower GI Series Market showcases a significant focus on Test Types, particularly in techniques such as Double-Contrast and Single-Contrast procedures. Each of these methods plays an essential role in the diagnostic process for gastrointestinal disorders, aiding physicians in visualizing the anatomy of the lower gastrointestinal tract more effectively. The Double-Contrast technique is particularly notable for its ability to enhance the detection of abnormalities by providing clearer images of the mucosal lining, thereby facilitating accurate diagnosis of conditions like polyps and carcinomas. In contrast, the Single-Contrast method, while simpler, is effective for quicker assessments, typically yielding satisfactory results for the evaluation of conditions such as diverticulosis. Collectively, these techniques dominate the market not only due to their efficacy but also owing to the growing prevalence of lower GI diseases in the US population, driven by factors including dietary habits and aging demographics. Furthermore, advancements in imaging technology contribute to improved outcomes, supporting the overall growth dynamics within the US Lower GI Series Market. Overall, understanding these Test Types is critical for stakeholders aiming to meet the increasing demand for effective gastrointestinal diagnostics. ### **Lower GI Series Market End Users Insights** The US Lower GI Series Market focuses on various end users, including hospitals, clinics, and laboratories, each playing a crucial role in the delivery of gastrointestinal imaging services. Hospitals remain prominent due to their comprehensive diagnostic capabilities, advanced technology, and emergency services, catering to a large patient population. Clinics, with their accessibility and cost-effectiveness, are increasingly preferred for routine screenings, thus contributing significantly to the growth of the market. Laboratories, essential for accurate diagnosis and analysis, support hospitals and clinics by providing vital data to aid in treatment decisions. Together, these end users reflect the growing demand for advanced imaging techniques in the US, motivated by increasing incidences of gastrointestinal disorders and the necessity for preventive measures. Market growth is driven by rising awareness, technological advancements in imaging equipment, and a shift towards outpatient care. However, challenges such as regulatory compliance and equipment costs persist but can be mitigated through strategic partnerships and innovation initiatives. Overall, the segmentation of the US Lower GI Series Market highlights the interdependent relationship between these key end users in responding to changing healthcare needs. ## **US Lower GI Series Market Key Players and Competitive Insights** The US Lower GI Series Market is characterized by a robust competitive environment, driven by advancements in imaging technology and increasing demand for diagnostic procedures that ensure precise assessments of gastrointestinal health. The market landscape is shaped by various players who are continually innovating their offerings to enhance performance and patient outcomes. As healthcare providers seek to adopt more efficient and accurate diagnostic tools, the competition intensifies, resulting in a focus on providing high-quality products and services. Key players are investing in research and development to introduce improved technologies that not only meet regulatory standards but also address the changing needs of healthcare providers and patients alike. The competitive dynamics are also influenced by factors such as product differentiation, strategic partnerships, and the growth of telehealth services, all of which are reshaping how lower gastrointestinal assessments are performed across the US. ### **Key Companies in the US Lower GI Series Market Include** ## **US Lower GI Series Market Industry Developments** Recent developments in the US Lower GI Series Market have showcased significant advancements and changes among key players. Siemens Healthineers and GE Healthcare continue to innovate with enhanced imaging technologies that improve diagnostic accuracy and patient experience. Amid ongoing trends towards value-based care, companies like Philips Healthcare and Fujifilm Holdings are expanding their portfolios to include more comprehensive solutions for gastrointestinal imaging. In terms of mergers and acquisitions, Boehringer Ingelheim completed its acquisition of a niche tech firm in March 2023, focusing on digital health solutions for gastrointestinal disorders, while Johnson and Johnson announced a strategic acquisition of a diagnostic company in January 2023, solidifying its presence in the market. The valuation of companies in this sector is projected to grow due to rising healthcare expenditures and increasing demand for early disease detection among several populations, particularly older adults. Additionally, significant events such as the FDA's approval of new imaging agents in June 2022 have bolstered the market's outlook. Overall, the competitive landscape is evolving as these companies pursue innovation and expand their market reach while addressing growing consumer needs. ## **US Lower GI Series Market Segmentation Insights** ### **Lower GI Series Market Application****Outlook** ### **Lower GI Series Market Test Types****Outlook** ### **Lower GI Series Market End Users****Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in the US is another significant driver for the lower gi-series market. With healthcare spending projected to reach approximately $6 trillion by 2027, there is a growing investment in diagnostic services, including lower gi-series procedures. This financial commitment from both public and private sectors is likely to enhance the availability and quality of gastrointestinal diagnostics. The lower gi-series market stands to benefit from this trend, as increased funding can lead to improved facilities, better-trained personnel, and more comprehensive patient care options, ultimately driving market growth. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic imaging are significantly influencing the lower gi-series market. Enhanced imaging techniques, such as high-definition endoscopy and advanced fluoroscopy, have improved the accuracy and efficiency of lower gastrointestinal examinations. These advancements not only facilitate better visualization of the intestinal tract but also reduce patient discomfort and procedure time. The lower gi-series market is experiencing a shift towards these modern technologies, which are expected to enhance diagnostic capabilities and patient throughput. As a result, healthcare facilities are increasingly investing in state-of-the-art equipment, further driving market growth. ### Growing Demand for Preventive Healthcare The shift towards preventive healthcare is a notable trend impacting the lower gi-series market. As awareness of the importance of early detection of gastrointestinal issues increases, more individuals are opting for routine screenings. This trend is particularly evident among the aging population, which is more susceptible to digestive disorders. The lower gi-series market is likely to see a surge in demand as healthcare providers recommend these procedures as part of comprehensive health assessments. Furthermore, the integration of preventive measures into healthcare policies may lead to increased insurance coverage for lower gi-series tests, making them more accessible to the general population. ### Increasing Prevalence of Digestive Disorders The rising incidence of digestive disorders in the US is a primary driver for the lower gi-series market. Conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) have seen a notable increase, with estimates suggesting that around 15-20% of the population may experience IBS at some point in their lives. This growing prevalence necessitates advanced diagnostic tools, thereby propelling demand for lower gi-series procedures. As healthcare providers seek to improve patient outcomes, the lower gi-series market is likely to benefit from increased utilization of these diagnostic methods, which are essential for accurate assessment and management of gastrointestinal conditions. ### Regulatory Support for Diagnostic Procedures Regulatory bodies in the US are increasingly supporting the development and implementation of advanced diagnostic procedures, which positively impacts the lower gi-series market. Initiatives aimed at improving patient safety and diagnostic accuracy are encouraging healthcare providers to adopt lower gi-series tests. The lower gi-series market is likely to experience growth as regulations evolve to facilitate the integration of innovative technologies and methodologies. This regulatory support not only enhances the credibility of lower gi-series procedures but also fosters an environment conducive to research and development, further propelling market expansion. ## Future Outlook The [Lower GI Series Market](https://www.marketresearchfuture.com/reports/lower-gi-series-market-771) is projected to grow at a 4.45% CAGR from 2025 to 2035, driven by increasing health awareness and technological advancements. **New opportunities:** - Development of advanced imaging technologies for enhanced diagnostic accuracy. - Expansion of telehealth services for remote GI series consultations. - Partnerships with healthcare providers for integrated patient management solutions. By 2035, the market is expected to achieve robust growth, reflecting evolving healthcare demands. ## Segment Insights ### By Procedure Type: Colonoscopy (Largest) vs. CT Colonography (Fastest-Growing) The US lower gi-series market showcases a diverse range of procedure types, with Colonoscopy holding the largest share among them. Following closely are Barium Enema, CT Colonography, and Fluoroscopy, each contributing to the market's dynamic landscape. The significant adoption of Colonoscopy stems from its effectiveness in detecting bowel conditions, establishing it as the preferred method among healthcare providers and patients alike. Growth trends indicate that CT Colonography is emerging as the fastest-growing segment, driven by technological advancements that enhance diagnostic accuracy and patient comfort. The increasing awareness of colorectal cancer prevention and the aging population are key drivers propelling the demand for these procedures. Overall, the market is set for a transformative period as innovative approaches gain traction. Colonoscopy (Dominant) vs. CT Colonography (Emerging) Colonoscopy, recognized as the dominant procedure in the US lower gi-series market, serves as an essential tool for the early detection of colorectal cancer, leading to its widespread acceptance and utilization. Its comprehensive visualization capabilities make it a go-to option for both diagnosis and therapeutic interventions. On the other hand, CT Colonography, labeled as an emerging procedure, is gaining traction due to its minimally invasive nature, offering a patient-friendly alternative to traditional methods. This segment is powered by advancements in imaging technology that allow for faster and more accurate results, positioning it as a key player in the future of gastrointestinal diagnostics. ### By Application: Diagnostic Imaging (Largest) vs. Routine Screening (Fastest-Growing) In the analysis of the US lower gi-series market, Diagnostic Imaging holds a significant share, making it the dominant application segment. It plays a crucial role in the accurate visualization of lower gastrointestinal issues, contributing to its extensive adoption in clinical settings. On the other hand, Routine Screening is emerging as a pivotal segment, with an increasing emphasis on preventive healthcare measures reflecting a shift in consumer and provider priorities. Recent trends indicate a growing demand for Routine Screening as healthcare systems prioritize early detection and intervention, driving its robust growth. Factors such as increasing public awareness about gastrointestinal health and advancements in imaging technologies are propelling this segment forward. Furthermore, evolving healthcare policies favoring routine check-ups are likely to enhance the market penetration of screening applications in the near future. Diagnostic Imaging (Dominant) vs. Therapeutic Intervention (Emerging) The Diagnostic Imaging segment of the US lower gi-series market is characterized by its comprehensive approach to diagnosing lower gastrointestinal disorders, utilizing advanced imaging technologies to deliver precise results. This segment is well-established, benefiting from a solid infrastructure in healthcare facilities and a robust network of specialists who rely on imaging for accurate diagnostics. Conversely, the Therapeutic Intervention segment is quickly gaining prominence as a new avenue for managing gastrointestinal conditions. This field combines technological advancements with minimally invasive techniques, making it increasingly attractive to both healthcare providers and patients. The growth of this emerging segment is fueled by innovations in endoscopic procedures and the rising preference for outpatient care, which offers convenience and reduces recovery times. ### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) The market share distribution among the end user segments shows that hospitals dominate the landscape of the US lower gi-series market. They account for a significant share, fueled by the increasing patient influx and advancements in healthcare facilities. In contrast, diagnostic laboratories are rapidly gaining traction, capturing a growing segment of the market as they provide specialized services that are crucial for patient diagnosis and management. Growth trends indicate that hospitals will continue to lead, but diagnostic laboratories are emerging as pivotal players due to the rising demand for early disease detection and preventive health measures. The expansion of outpatient services and technological innovations in diagnostic tools are key drivers contributing to the growth of these end user segments within the market. Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging) Hospitals represent the dominant end user segment in the US lower gi-series market, known for their comprehensive range of services and ability to integrate advanced diagnostic technologies. Their substantial share is supported by established infrastructure and a robust patient base, enabling them to continually adapt to the evolving healthcare demands. On the other hand, diagnostic laboratories are considered an emerging segment, characterized by their focus on specialized testing and quick turnaround times. This segment is capitalizing on advancements in molecular diagnostics and imaging technologies, attracting hospitals and outpatient clinics looking to enhance efficiency and accuracy in gastrointestinal assessments. ### By Product Type: Contrast Media (Largest) vs. Imaging Equipment (Fastest-Growing) In the US lower gi-series market, Contrast Media leads the segment with a significant share, reflecting its critical role in enhancing imaging quality. Imaging Equipment and Consumables also hold notable positions, while Accessories contribute lesser but essential functionalities. The distribution demonstrates a competitive landscape, with Contrast Media maintaining a stronghold due to its established usage in diagnostic procedures. The growth trends show Imaging Equipment emerging rapidly as the fastest-growing segment, driven by technological advancements and increasing demand for non-invasive diagnostic techniques. The push for enhanced imaging quality and patient safety contributes significantly to the growth of these segments. Additionally, the rise of chronic gastrointestinal diseases necessitates improved imaging solutions, further boosting market dynamics. Contrast Media (Dominant) vs. Accessories (Emerging) Contrast Media serves as the dominant segment in the US lower gi-series market, recognized for its pivotal role in facilitating high-quality imaging, which is vital for accurate diagnosis. This segment is characterized by its robust application in various diagnostic scenarios, leading to consistent demand. On the other hand, Accessories are viewed as an emerging segment, providing necessary support products that enhance the functionality of main equipment. Although their market share is smaller, Accessories are increasingly recognized for their importance in the overall diagnostic process, aligning with the trend towards comprehensive healthcare solutions that prioritize patient comfort and procedural efficiency. ## Competitive Benchmarking The lower gi-series market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and technological advancements. Key players such as Bayer AG (DE), Abbott Laboratories (US), and Siemens Healthineers (DE) are actively pursuing strategies that emphasize product development and market expansion. Bayer AG (DE) has focused on enhancing its diagnostic capabilities, while Abbott Laboratories (US) is leveraging its strong portfolio in gastrointestinal diagnostics to capture a larger market share. Siemens Healthineers (DE) appears to be concentrating on integrating advanced imaging technologies into its offerings, thereby enhancing diagnostic accuracy and efficiency. Collectively, these strategies contribute to a dynamic competitive environment where innovation and operational excellence are paramount.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the lower gi-series market is moderately fragmented, with several players vying for dominance. This fragmentation allows for a diverse range of products and services, yet the influence of major players remains significant, as they set benchmarks for quality and innovation that smaller firms strive to meet. In October Abbott Laboratories (US) announced the launch of a new line of gastrointestinal diagnostic tests aimed at improving patient outcomes through faster and more accurate results. This strategic move is likely to bolster Abbott's position in the market, as it addresses the growing demand for rapid diagnostics in gastrointestinal health. The introduction of these tests not only enhances Abbott's product portfolio but also aligns with the broader trend of increasing patient-centric healthcare solutions. In September Siemens Healthineers (DE) unveiled a partnership with a leading telehealth provider to integrate remote monitoring capabilities into its lower gi-series diagnostic tools. This collaboration is indicative of a shift towards digital health solutions, allowing for real-time data collection and analysis, which could significantly improve patient management and treatment outcomes. Such strategic alliances are becoming increasingly vital as healthcare providers seek to enhance service delivery through technology. In August Bayer AG (DE) expanded its research and development efforts by investing €50 million in a new facility dedicated to gastrointestinal diagnostics. This investment underscores Bayer's commitment to innovation and its recognition of the growing importance of advanced diagnostic tools in the lower gi-series market. By enhancing its R&D capabilities, Bayer is positioning itself to lead in the development of next-generation diagnostic solutions. As of November current trends in the lower gi-series market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage complementary strengths and enhance their market offerings. Looking ahead, it is anticipated that competitive differentiation will evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution suggests that companies that prioritize these areas will likely emerge as leaders in the lower gi-series market. ## Recent News & Developments Recent developments in the US Lower GI Series Market have showcased significant advancements and changes among key players. Siemens Healthineers and GE Healthcare continue to innovate with enhanced imaging technologies that improve diagnostic accuracy and patient experience. Amid ongoing trends towards value-based care, companies like Philips Healthcare and Fujifilm Holdings are expanding their portfolios to include more comprehensive solutions for gastrointestinal imaging. In terms of mergers and acquisitions, Boehringer Ingelheim completed its acquisition of a niche tech firm in March 2023, focusing on digital health solutions for gastrointestinal disorders, while Johnson and Johnson announced a strategic acquisition of a diagnostic company in January 2023, solidifying its presence in the market. The valuation of companies in this sector is projected to grow due to rising healthcare expenditures and increasing demand for early disease detection among several populations, particularly older adults. Additionally, significant events such as the FDA's approval of new imaging agents in June 2022 have bolstered the market's outlook. Overall, the competitive landscape is evolving as these companies pursue innovation and expand their market reach while addressing growing consumer needs. ## Report Scope | MARKET SIZE 2024 | 382.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 399.21(USD Million) | | MARKET SIZE 2035 | 616.8(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.45% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bayer AG (DE), Abbott Laboratories (US), Fujifilm Holdings Corporation (JP), Siemens Healthineers (DE), General Electric Company (US), Medtronic plc (IE), Hologic, Inc. (US), Philips Healthcare (NL) | | Segments Covered | Procedure Type, Application, End User, Product Type | | Key Market Opportunities | Emerging technologies in imaging and diagnostics enhance accuracy in the lower gi-series market. | | Key Market Dynamics | Rising consumer awareness drives demand for lower gastrointestinal series procedures amid evolving healthcare regulations. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US lower gi-series market in 2024?** A: The overall market valuation was $382.2 Million in 2024. **Q: What is the projected market valuation for the US lower gi-series market by 2035?** A: The projected valuation for 2035 is $616.8 Million. **Q: What is the expected CAGR for the US lower gi-series market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period is 4.45%. **Q: Which procedure type had the highest valuation in the US lower gi-series market in 2024?** A: Colonoscopy had the highest valuation at $152.88 Million in 2024. **Q: What are the key application segments in the US lower gi-series market?** A: Key application segments include Diagnostic Imaging, Routine Screening, Disease Monitoring, and Therapeutic Intervention. **Q: Which end user segment contributed the most to the US lower gi-series market in 2024?** A: Hospitals contributed the most, with a valuation of $114.66 Million in 2024. **Q: What product types are included in the US lower gi-series market?** A: Product types include Contrast Media, Imaging Equipment, Consumables, and Accessories. **Q: Who are the key players in the US lower gi-series market?** A: Key players include Bayer AG, Abbott Laboratories, Fujifilm Holdings Corporation, Siemens Healthineers, General Electric Company, Medtronic plc, Hologic, Inc., and Philips Healthcare. **Q: What was the valuation of the Barium Enema segment in the US lower gi-series market in 2024?** A: The Barium Enema segment was valued at $76.44 Million in 2024. **Q: How does the projected growth of the US lower gi-series market compare to its 2024 valuation?** A: The market is expected to grow from $382.2 Million in 2024 to $616.8 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-lower-gi-series-market-19974*